Last reviewed · How we verify
COVID19 pneumonia requiring supplemental oxygen — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Anakinra | Kineret | Biovitrum Ab | Interleukin-1 Receptor Antagonist | Interleukin-1 receptor, type I | 2001-01-01 | |
| Kineret | ANAKINRA | Biovitrum Ab | Interleukin-1 Receptor Antagonist [EPC] | Interleukin-1 receptor, type I | 2001-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Biovitrum Ab · 2 drugs in COVID19 pneumonia requiring supplemental oxygen
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in COVID19 pneumonia requiring supplemental oxygen:
- COVID19 pneumonia requiring supplemental oxygen treatment updates — RSS
- COVID19 pneumonia requiring supplemental oxygen treatment updates — Atom
- COVID19 pneumonia requiring supplemental oxygen treatment updates — JSON
Cite this brief
Drug Landscape (2026). COVID19 pneumonia requiring supplemental oxygen — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/covid19-pneumonia-requiring-supplemental-oxygen. Accessed 2026-06-10.
Related
- COVID19 pneumonia requiring supplemental oxygen full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing